DOES SERUM SOLUBLE VASCULAR ENDOTHELIAL GROWTH FACTOR LEVELS HAVE DIFFERENT IMPORTANCE IN PEDIATRIC ACUTE LEUKEMIA AND MALIGNANT LYMPHOMA PATIENTS?

REFERENCES

• Folkman J. Tumor angiogenesis: therapeutic implications. N Engl J Med. 1971;285:1182–1186.
   PubMed Web of Science ®Google Scholar
• Dong X, Han ZC, Yang RC. Angiogenesis and antiangiogenic therapy in hematologic malignancies. Crit Rev Oncol Hematol. 2007;62:105–118.
   PubMed Web of Science ®Google Scholar
• Bellamy WT, Richter L. Expression of vascular endothelial growth factor and its receptors in hematopoietic malignancies. Cancer Res. 1999;59:728–733.
   PubMed Web of Science ®Google Scholar
• Aguayo A, Kantarjian H, Manshouri T, Angiogenesis in acute and chronic leukemias and myelodysplastic syndromes. Blood. 2000;96:2240–2245.
   PubMed Web of Science ®Google Scholar
• Bhatti SS, Kumar L, Dinda AK, Prognostic value of bone marrow angiogenesis in multiple myeloma: use of light microscopy as well as computarized image analyzer in the assesment of microvessel density and total vascular area in multiple myeloma and its correlation with various clinical, histological and laboratory parameters. Am J Hematol. 2006;81:649–656.
   PubMed Web of Science ®Google Scholar
• De Raeve H, Van Marck E, Van Camp B, Angiogenesis and the role of bone marrow endothelial cells in haematological malignancies. Histol Histopathol. 2004;19:935–950.
   PubMed Web of Science ®Google Scholar
• Negaard HFS, Iversen N, Bowitz-Lothe IM, Increased bone marrow microvascular density in haematological malignancies is associated with differential regulation of angiogenic factors. Leukemia. 2009;23:162–169.
   PubMed Web of Science ®Google Scholar
• Lundberg LG, Hellström-Lindberg E, Kanter-Lewensohn L, Angiogenesis in relation to clinical stage, apoptosis and prognostic score in myelodysplastic syndromes. Leuk Res. 2006;30:247–253.
   PubMed Web of Science ®Google Scholar
• Kerbel RS. Tumor angiogenesis. N Engl J Med. 2008;19:2039–2048.
   Google Scholar
• Gerber HP, Ferrara N. The role of VEGF in normal and neoplastic hematopoiesis. J Mol Med. 2003;81:20–31.
   PubMed Web of Science ®Google Scholar
• Hussong JW, Rodgers GM, Shami PJ. Evidence of increased angiogenesis in patients with acute myeloid leukemia. Blood. 2000;95:309.
   PubMedGoogle Scholar
• Padro T, Ruiz S, Bieker R, Increased angiogenesis in the bone marrow of patients with acute myeloid leukemia. Blood. 2000;95:2637–2644.
   PubMed Web of Science ®Google Scholar
• De Bont ESJM, Rosati S, Jacobs S, Increased bone marrow vascularization in patients with acute myeloid leukemia: a possible role for vascular endothelial growth factor. Br J Haematol. 2001;113:296–304.
   PubMed Web of Science ®Google Scholar
• Mirshahi P, Rafii A, Vincent L, Vasculogenic mimicry of acute leukemic bone marrow stromal cells. Leukemia. 2009;23:1039–1048.
   PubMed Web of Science ®Google Scholar
• Aguayo A, Estey E, Kantarjian H, Cellular vascular endothelial growth factor is a predictor of outcome in patients with acute myeloid leukemia. Blood. 1999;94:3717–3721.
   PubMed Web of Science ®Google Scholar
• Fiedler W, Graeven U, Ergün S, Expression of FLT4 and its ligand VEGF-C in acute myeloid leukemia. Leukemia. 1997;11:1234–1237.
   PubMedGoogle Scholar
• Padro T, Bieker R, Ruiz S, Overexpression of vascular endothelial growth factor (VEGF) and its cellular receptor KDR (VEGFR-2) in the bone marrow of patients with acute myeloid leukemia. Leukemia. 2002;16:1302–1310.
   PubMed Web of Science ®Google Scholar
• Fiedler W, Graeven U, Ergün S, Vascular endothelial cell growth factor, a possible paracrine growth factor in human acute myeloid leukemia. Blood. 1997;89:1870–1875.
   PubMed Web of Science ®Google Scholar
• Gerber HP, Malik AK, Solar GP, VEGF regulates hematopoietic stem cell survival by an internal autocrine loop mechanism. Nature. 2002;417:954–958.
   PubMed Web of Science ®Google Scholar
• Hiramatsu A, Miwa H, Shikami M, Disease-specific expression of VEGF and its receptors in AML cells: possible autocrine pathway of VEGF/type1 receptor of VEGF in t(15;17) AML and VEGF/type2 receptor of VEGF in t(8;21) AML. Leuk Lymphoma. 2006;47:89–95.
   PubMed Web of Science ®Google Scholar
• Jeha S, Smith FO, Estey E, Comparison between pediatric acute myeloid leukemia (AML) and adult AML in VEGF and KDR (VEGF-R2) protein levels. Leuk Res. 2002;26:399–402.
   PubMed Web of Science ®Google Scholar
• Avramis IA, Panoysan EH, Dorey F, Correlation between high vascular endothelial growth factor-A serum levels and treatment outcome in patients with standart-risk acute lymphoblastic leukemia: a report from Children's Oncology Group Study CCG-1962. Clin Cancer Res. 2006;12:6978–6984.
   PubMed Web of Science ®Google Scholar
• Pule MA, Gullman C, Dennis D, Increased angiogenesis in bone marrow of children with acute lymphoblastic leukemia has no prognostic significance. Br J Haematol. 2002;118:991–998.
   PubMed Web of Science ®Google Scholar
• Perez-Atayde AR, Sallan SE, Tedrow U, Spectrum of tumor angiogenesis in the bone marrow of children with acute lymphoblastic leukemia. Am J Pathol. 1997;150:815–821.
   PubMed Web of Science ®Google Scholar
• Schneider P, Vasse M, Sbaa-Ketata E, The growth of highly proliferative acute lymphoblastic leukemia may be independent of stroma and/or angiogenesis. Leukemia. 2001;15:1143–1145.
   PubMed Web of Science ®Google Scholar
• Faderl S, Do KA, Johnson MM, Angiogenic factors may have a different prognostic role in adult lymphoblastic leukemia. Blood. 2005;106:4303–4307.
   PubMed Web of Science ®Google Scholar
• Ji RC. Lymph node lymphangiogenesis: a new concept for modulating tumor metastasis and inflammatory process. Histol Histopathol. 2009;24:377–384.
   PubMed Web of Science ®Google Scholar
• Ribatti D. Lymphangiogenesis in haematological malignancies. Leuk Res. 2009;33:753–755.
   PubMed Web of Science ®Google Scholar
• Koster A, Raemaekers JM. Angiogenesis in malignant lymphoma. Curr Opin Oncol. 2005;17:611–616.
   PubMed Web of Science ®Google Scholar
• Kadowaki I, Ichinohasama R, Harigae H, Accelerated lymphangiogenesis in malignant lymphoma: possible role of VEGF-A and VEGF-C. Br J Haematol. 2005;130:869–877.
   PubMed Web of Science ®Google Scholar
• Giles FJ, Vose JM, Do KA. Clinical relevance of circulating angiogenic factors in patients with non-Hodgkin's lymphoma or Hodgkin's lymphoma. Leuk Res. 2004;28:595–604.
   PubMed Web of Science ®Google Scholar
• Salven P, Orpana A, Teerenhovi L. Simultaneous elevation in the serum concentrations of the angiogenic growth factors VEGF and bFGF is an independent predictor of poor prognosis in non-Hodgkin's lymphoma: a single institution study of 200 patients. Blood. 2000;96:3712–3718.
   PubMed Web of Science ®Google Scholar
• Paydas S, Seydaoglu G, Ergin M, The prognostic significance of VEGF-C and VEGF-A in non-Hodgkin lymphomas. Leuk Lymphoma. 2009;50:366–373.
   PubMed Web of Science ®Google Scholar
• Younes A. Angiogenesis in lymphoma: a short review. Curr Mol Med. 2005;5:609–613.
   PubMed Web of Science ®Google Scholar
• Vacca A, Ribatti D, Roncali L, Angiogenesis in B-cell lymphoproliferative disease. Biological and clinical studies. Leuk Lymphoma. 1995;20:27–38.
   PubMed Web of Science ®Google Scholar
• Margolin JF, Steuber CP, Poplack DG. Acute lymphoblastic leukemia. In: Pizzo PA, Poplack DG, eds. Principles and Practice of Pediatric Oncology. Philadelphia, PA: Lippincott Williams & Wilkins; 2006:538–590.
   Google Scholar
• Golub TR, Arceci RJ. Acute myelogenous leukemia. In: Pizzo PA, Poplack DG, eds. Principles and Practice of Pediatric Oncology. Philadelphia, PA: Lippincott Williams & Wilkins; 2006:591–645.
   Google Scholar
• Hudson MM, Onciu M, Donaldson SS. Hodgkin lymphoma. In: Pizzo PA, Poplack DG, eds. Principles and Practice of Pediatric Oncology. Philadelphia, PA: Lippincott Williams & Wilkins; 2006:695–721.
   Google Scholar
• Link MP, Weinstein HJ. Malignant non-hodgkin lymphomas in children. In: Pizzo PA, Poplack DG, eds. Principles and Practice of Pediatric Oncology. Philadelphia, PA: Lippincott Williams & Wilkins; 2006:722–747.
   Google Scholar
• Woods WG, Kobrinsky N, Buckley JD, Timed-sequential induction therapy improves postremission outcome in acute myeloid leukemia: a report from the Children's Cancer Group. Blood. 1996;87:4979–4989.
   PubMed Web of Science ®Google Scholar
• Seibel NL, Steinherz PG, Sather HN, Early postinduction intensification therapy improves survival for children and adolescents with high-risk acute lymphoblastic leukemia: a report from the Children's Oncology Group. Blood. 2008;111:2548–2555.
   PubMed Web of Science ®Google Scholar
• Creutzig U, Berthold F, Boos J, AML-BFM-Studien-Gruppe. Improved treatment results in children with AML: results of study AML-BFM 93. Klin Padiatr. 2001;213:175–185.
   PubMed Web of Science ®Google Scholar
• Sandlund JT, Pui CH, Zhou Y, Effective treatment of advanced-stage childhood lymphoblastic lymphoma without prophylactic cranial irradiation: results of St Jude NHL13 study. Leukemia. 2009;23:1127–1130.
   PubMed Web of Science ®Google Scholar
• Carbone PP, Kaplan HS, Musshoff K, Report of the Committee on Hodgkin's Disease Classification. Cancer Res. 1971;31:1860–1861.
   PubMed Web of Science ®Google Scholar
• Murphy SB. Current concepts in cancer: childhood non-Hodgkin's lymphoma. N Engl J Med. 1978;299:1446–14478.
   PubMed Web of Science ®Google Scholar
• Schellong G, Hörnig I, Brämswig J, Significance of procarbazine in the chemotherapy of Hodgkin's disease—a report of the Cooperative Therapy Study DAL-HD-85. Klin Padiatr. 1988;200:205–213.
   PubMed Web of Science ®Google Scholar
• Griffin TC, Bowman WP, Winick NJ, Treatment of advanced stage diffuse, small non-cleaved cell lymphoma in childhood: further experience with Total Therapy B. Med Ped Oncol. 1994;23:393–399.
   PubMedGoogle Scholar
• Reiter A, Shrappe M, Ludwig W, Intensive ALL-type therapy without local radiotherapy provides a 90% event-free survival for children with T-cell lymphoplasmacytic lymphoma: a BFM group report. Blood. 2000;95:416–421.
   PubMed Web of Science ®Google Scholar
• Matsumoto Y, Nomura K, Kanda-Akano Y, Successful treatment with Erwinia L-asparaginase for recurrent natural killer/T cell lymphoma. Leuk Lymphoma. 2003;44:879–882.
   PubMed Web of Science ®Google Scholar
• Liersh R, Schliemann C, Bieker R, Expression of VEGF-C and its receptor VEGFR-3 in the bone marrow of patients with acute myeloid leukaemia. Leuk Res. 2008;32:954–961.
   PubMed Web of Science ®Google Scholar
• Joukov V, Pajusola K, Kaipainen A, A novel vascular endothelial growth factor, VEGF-C, is a ligand for the Flt4 (VEGFR-3) and KDR (VEGFR-2) receptor tyrosine kinases. EMBO J. 1996;15:290–298.
   PubMed Web of Science ®Google Scholar
• Cao Y, Linden P, Farnebo J, Vascular endothelial growth factor C induces angiogenesis invivo. Proc Natl Acad Sci U S A. 1998;95:14389–14394.
   PubMed Web of Science ®Google Scholar
• Dias S, Choy M, Alitalo K, Vascular endothelial growth factor (VEGF)-C signaling through FLT-4 (VEGFR-3) mediates leukemic cell proliferation, survival, and resistance to chemotherapy. Blood. 2002;99:2179–2184.
   PubMed Web of Science ®Google Scholar
• Bautz F, Rafii S, Kanz L, Expression and secretion of vascular endothelial growth factor-A by cytokine-stimulated hematopoietic progenitor cells: possible role in the hematopoietic microenvironment. Exp Hematol. 2000;28:700–706.
   PubMed Web of Science ®Google Scholar
• Litwin C, Leong KG, Zapf R, Role of microenvironment in promoting angiogenesis in acute myeloid leukemia. Am J Hematol. 2002;70:22–30.
   PubMed Web of Science ®Google Scholar
• Kusumanto YH, Dam WA, Hospers GAP, Platelets and granulocytes, in particular the neutrophils, form important compartments for circulating vascular endothelial growth factor. Angiogenesis. 2003;6:283–287.
   PubMedGoogle Scholar
• Kut C, Gabhann FM, Popel AS. Where is VEGF in the body? A meta-analysis of VEGF distribution in cancer. Br J Cancer. 2007;97:978–985.
   PubMed Web of Science ®Google Scholar
• Koomagi R, Zintl F, Sauerbrey A, Vascular endothelial growth factor in newly diagnosed and recurrent childhood acute lymphoblastic leukemia as measured by real-time quantitative polymerase chain reaction. Clin Cancer Res. 2001;7:3381–3384.
   PubMed Web of Science ®Google Scholar
• Lyu CJ, Rha SY, Won SC. Clinical role of bone marrow angiogenesis in childhood acute lymphocytic leukemia. Yonsei Med J. 2007;48:171–175.
   PubMed Web of Science ®Google Scholar
• Yetgin S, Yenicesu I, Cetin M, Clinical importance of serum vascular endothelial and basic fibroblast growth factors in children with acute lymphoblastic leukemia. Leuk Lymphoma. 2001;42:83–88.
   PubMed Web of Science ®Google Scholar
• Aref S, Salama O, Shamaa S, Angiogenesis factor pattern differs in acute lymphoblastic leukemia and chronic lymphocytic leukemia. Hematology. 2007;12:319–324.
   PubMed Web of Science ®Google Scholar
• Nagy JA, Vasile E, Feng D, Vascular permeability factor/vascular endothelial growth factor induces lymphangiogenesis as well as angiogenesis. J Exp Med. 2002;196:1497–1506.
   PubMed Web of Science ®Google Scholar
• Korkolopoulou P, Thymara I, Kavantzas N, Angiogenesis in Hodgkin's lymphoma: a morphometric approach in 286 patients with prognostic implications. Leukemia. 2005;19:894–900.
   PubMed Web of Science ®Google Scholar
• Jorgensen JM, Sorensen FB, Bendix K, Angiogenesis in non-Hodgkin's lymphoma:clinico-pathological correlations and prognostic significance in specific subtypes. Leuk Lymphoma. 2007;48:584–595.
   PubMed Web of Science ®Google Scholar
• Hazar B, Paydas S, Zorludemir S, Prognostic significance of microvessel density and vascular endothelial growth factor (VEGF) expression in non-Hodgkin's lymphoma. Leuk Lymphoma. 2003;44:2089–2093.
   PubMed Web of Science ®Google Scholar
• Niitsu N, Okamato M, Nakamine H, Simultaneous elevation of the serum concentrations of vascular endothelial growth factor and interleulin-6 as independent predictors of prognosis in aggressive non-Hodgkin's lymphoma. Eur J Haematol. 2002;68:91–100.
   PubMed Web of Science ®Google Scholar
• Bertolini F, Paolucci M, Peccatori F, Angiogenic growth factors and endostatin in non-Hodgkin's lymphoma. Br J Haematol. 1999;106:504–509.
   PubMed Web of Science ®Google Scholar
• Doussis-Anagnostopoulou IA, Talks KL, Turley H, Vascular endothelial growth factor (VEGF) is expressed by neoplastic Hodgkin-Reed-Sternberg cells in Hodgkin's disease. J Pathol. 2002;197:677–683.
   PubMed Web of Science ®Google Scholar
• Agarwal B, Naresh KN. Re: Doussis-Anagnostopoulou et al. Vascular endothelial growth factor (VEGF) is expressed by neoplastic Hodgkin-Reed-Sternberg cells in Hodgkin's disease. J Pathol. 2002;197:677–683.
   PubMed Web of Science ®Google Scholar
• Citak EC, Oguz A, Karadeniz C, Immunohistochemical expression of angiogenic cytokines in childhood Hodgkin lymphoma. Pathol Res Pract. 2008;204:89–96.
   PubMed Web of Science ®Google Scholar
• De Jonge HJM, Weidenaar AC, ter Elst A, Endogenous vascular endothelial growth factor-C expression is associated with decreased drug responsiveness in childhood acute myeloid leukemia. Clin Cancer Res. 2008;14:924–930.
   PubMed Web of Science ®Google Scholar